Paradigm shift in NMDA receptor drug development.
Low-affinity, uncompetitive antagonists with rapid 'off-rates', such as memantine offer protection from dementia and other neurological disorders, but break all the old rules of screening for new drugs by high-affinity binding.
Lipton
Stuart A
SA
Chen
H-S Vincent
HS
D004353:Drug Evaluation, Preclinical; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*
D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate